Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 230

Douyu restarts $944m IPO plans

After temporarily halting the IPO in May due to US-China tensions, Douyu has relaunched its efforts with a target of $944m in proceeds and moved its proposed listing from NYSE to Nasdaq.

Jul 9, 2019

PRG acquires Metalysis

Power Resources Group has bought University of Cambridge-founded metal power producer Metalysis, which had plunged into administration last month.

Jul 8, 2019

IndiaMart takes stock of public market

IndiaMart, backed by Intel Capital and Brand Equity Treaty, has listed on the National Stock Exchange after raising $69m in its initial public offering.

Jul 8, 2019

LiveRamp scores Data Plus Math acquisition

Comcast Ventures has exited television advertising analytics platform Data Plus Math in a reported $150m purchase by LiveRamp.

Jul 8, 2019

Codiak revokes $86m IPO filing

Codiak BioSciences, based on research at the universities of Gothenburg and Texas, hoped to raise $86m in an initial public offering but has now withdrawn those plans.

Jul 5, 2019

Red Dot marks acquisition spot

GMO and Telkom Indonesia-backed Red Dot Payments was valued at $65m in a deal in which Naspers subsidiary PayU bought a majority stake.

Jul 5, 2019

Ucommune to move into IPO neighbourhood

The co-working space service is aiming to raise up to $200m in an initial public offering in the US next year, with multiple real estate developers in line for exits.

Jul 4, 2019

Karuna caps off initial public offering

PureTech Health spinoff Karuna Therapeutics has upscaled its IPO to nearly $103m, after its shares rose by more than 50% in its first days of trading.

Jul 4, 2019

Codiak revokes $86m IPO filing

Codiak Biosciences has withdrawn its proposed offering citing unfavourable market conditions, delaying an exit for investors including Alexandria Real Estate Equities.

Jul 4, 2019

Morphic takes more money in $104m IPO

Small molecule therapeutic developer Morphic, based on research at Harvard Medical School, has boosted its initial public offering from $90m to nearly $104m.

Jul 3, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here